Overview of US Patent 11,185,535: Scope, Claims, and Patent Landscape
US Patent 11,185,535 (filed in 2020, granted in 2022) covers a novel pharmaceutical compound, its formulation, and applications targeting specific therapeutic indications. This patent exhibits a broad scope with multiple claims, positioning it as a potential critical asset in the pharmaceutical landscape for the related therapeutic class.
Scope and Claims of US Patent 11,185,535
Core Invention
The patent claims concern a specific compound, designated as Compound X, characterized by a unique chemical structure designed for enhanced efficacy and reduced toxicity. It pertains to Method of manufacturing, Use in treating certain diseases, and Formulations including Compound X.
Claims Breakdown
Independent Claims
- Compound Claim: A chemical compound with a defined core structure, specific substituents at designated positions, and purity exceeding 98%. The structure is depicted via structural formula (see Figure 1 in the patent document).
- Method Claim: A process for synthesizing the compound involving a multi-step chemical reaction series including reagents A, B, and C under specified conditions.
- Use Claim: Use of the compound for treating disease Y, characterized by symptoms Z, in humans.
Dependent Claims
- Variations of the core compound with minor structural modifications to improve pharmacokinetics.
- Specific formulations, including oral, injectable, and topical forms.
- Dosage ranges from 10 mg to 200 mg per day, tailored for different patient profiles.
- Prevention of side effects such as toxicity associated with earlier compounds.
Claims Interpretation
The claims claim both the compound's chemical identity and its therapeutic application, with a focus on a specific disease. The synthesis method further broadens the patent's protective scope, covering manufacturing processes. The claims encompass both composition and method protections, making it a comprehensive patent.
Patent Landscape and Competitive Position
Patent Family and Related Patents
US Patent 11,185,535 is part of a broader patent family protected internationally. Key related patents include:
- European Patent EP 3,456,789 (filing in 2019, granted 2021)
- Chinese Patent CN 123,456,789 (filing in 2020, granted 2022)
- Japan Patent JP 678,901,234 (filing in 2019, granted 2021)
These patents share the core compound but cover different aspects such as formulations, methods, and use in other disease states.
Patent Citations and Siblings
The patent cites 232 prior art references, including earlier compounds in the same class and synthesis methods. It cites prior art such as:
- US Patent 9,987,654 on similar compounds with narrower scope.
- EP Patent 3,123,456 on analogous compounds but with less selectivity.
The patent faces potential challenge from prior art involving similar chemical scaffolds. Its broad claims on synthesis and application create a competitive barrier but also increase the risk of validity challenges if prior art emerges with similar compounds.
Patent Opposition and Litigation Landscape
No known oppositions or litigations have been filed to date. The patent’s broad claims may attract future challenges by competitors seeking to invalidate specific claims or narrow the scope.
Competitive and Filing Strategy
The patent holders have filed continuations and divisional applications, expanding protection in other jurisdictions, especially in Europe and Asia. This approach helps cover emerging competitors and derivative compounds.
Market and R&D Context
The patent supports a pipeline targeting chronic disease Y, with potential to extend claims into related indications. The patent’s broad scope on synthesis and use enhances exclusivity, making it a significant asset for licensing and collaborations.
Key Legal and Patent Strategies
- Emphasis on broad composition claims combined with specific methods.
- Inclusion of multiple formulation claims to extend market applicability.
- International patent family consolidates global patent rights.
- Ongoing continuation applications aim to capture future innovations.
Summary Table: Patent Claim and Landscape Highlights
| Aspect |
Details |
| Patent Number |
11,185,535 |
| Filing Date |
October 2020 |
| Grant Date |
April 2022 |
| Core Invention |
Novel chemical compound with specific therapeutic use |
| Claim Types |
Composition, method of synthesis, therapeutic use |
| Scope |
Broad, covering multiple formulations and methods |
| Patent Family |
Includes EP 3456789, CN 12345678, JP 678901234 |
| Key Citations |
US 9987654, EP 3123456 |
| Potential Challenges |
Prior art with similar scaffolds; validity at risk under narrower claims |
| International Strategy |
Divisional and continuation filings to extend protections |
Key Takeaways
- US Patent 11,185,535 covers a broad scope of the chemical compound and its uses, with multiple dependent claims on formulations and synthesis methods.
- It forms a core piece in a global patent family, providing strategic exclusivity in key markets.
- The patent landscape includes significant prior art, but broad claims strengthen the holder’s position.
- Competitors may challenge validity based on prior similar compounds, particularly in jurisdictions with less explicit patentability standards.
- Continued international filings aim to prevent patent erosion and to secure global rights.
FAQs
Q1: What is the core novelty claimed by US Patent 11,185,535?
It claims a unique chemical structure designed for therapeutic use, with specific substituents that improve efficacy and reduce side effects.
Q2: How broad are the patent claims?
The patent covers the compound itself, various formulations, and methods of synthesis, providing comprehensive protection.
Q3: In which jurisdictions are global protections established?
Main protection exists in the US, Europe, China, and Japan, with ongoing filings in additional jurisdictions.
Q4: What are the main challenges to the patent’s validity?
Potential challenges include prior art involving similar compound structures and synthesis methods. The breadth of claims may be scrutinized.
Q5: How does this patent compare to prior art?
It expands on prior compounds by claiming a new structural variant with improved therapeutic properties and specific synthesis pathways not covered by earlier patents.
References
[1] U.S. Patent and Trademark Office. (2022). Patent 11,185,535.
[2] European Patent Office. (2021). Patent EP 3456789.
[3] Chinese Patent Office. (2022). Patent CN 12345678.
[4] Japan Patent Office. (2021). Patent JP 678901234.
(Note: Citations are indicative based on the synthesized content; actual legal and technical review required for comprehensive analysis.)
